Ts65Dn mice received Rimonabant through drinking water, reaching a final dose of 0.5 mg/kg/day. At 10 months of age, treated male and female mice showed memory improvement assessed by the discrimination index in NORT. In a separate analysis at 10 months of age, dorsal hippocampal CB1R protein levels did not differ between vehicle- and Rimonabant-treated Ts65Dn mice. [2]
Memory improvement in male and female Ts65Dn mice
Animal study · Ts65Dn male (C) and female (D) mice; males: Ts65Dn VEH n = 6; Ts65Dn RIM n = 12; females: Ts65Dn VEH n = 10; Ts65Dn RIM n = 9 [2]
Male and female Ts65Dn mice received Rimonabant through drinking water, reaching a final dose of 0.5 mg/kg/day. At 10 months of age, memory improvement was observed in treated males and females, assessed by the discrimination index in NORT.
Conditions shared by the study groups
- Route
- through the drinking water
- Treatment course
- from PND21 until 10 months of age; During the first 2.5 months of treatment mice received rimonabant 0.1 mg/kg/day. This dose was increased to the final concentration of 0.5 mg/kg/day by 3.5 months of age.
- Vehicle
- 0.3% 2‐hydroxypropyl‐β‐cyclodextrin in water
- Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day
- Model: Ts65Dn male (C) and female (D) mice; males: Ts65Dn VEH n = 6; Ts65Dn RIM n = 12; females: Ts65Dn VEH n = 10; Ts65Dn RIM n = 9
Methods and source locations
Compound reported in the paper: Rimonabant
The paper names Rimonabant without stating the salt or form; not verified as the hydrochloride form supplied as A11548. No dose conversion or lot validation.
METHODS > Drug treatments (S44, S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S144); FIGURE 2 legend (S190)
Discrimination index in NORT: Discrimination index in NORT; comparator: Ts65Dn VEH — RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S144); FIGURE 2 legend (S190)
Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day · METHODS > Drug treatments (S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S144); FIGURE 2 legend (S190)
Hippocampal CB1R protein levels in Ts65Dn mice
Animal study · Ts65Dn mice; 10 months of age; Ts65Dn VEH, n = 4, Ts65Dn RIM, n = 6 [2]
Ts65Dn mice received Rimonabant through drinking water, reaching a final dose of 0.5 mg/kg/day. At 10 months of age, dorsal hippocampal western blot analysis showed no difference in CB1R protein levels between vehicle- and Rimonabant-treated mice.
Conditions shared by the study groups
- Route
- through the drinking water
- Treatment course
- from PND21 until 10 months of age; During the first 2.5 months of treatment mice received rimonabant 0.1 mg/kg/day. This dose was increased to the final concentration of 0.5 mg/kg/day by 3.5 months of age.
- Vehicle
- 0.3% 2‐hydroxypropyl‐β‐cyclodextrin in water
- Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day
- Model: Ts65Dn mice; 10 months of age; Ts65Dn VEH, n = 4, Ts65Dn RIM, n = 6
Methods and source locations
Compound reported in the paper: Rimonabant
The paper names Rimonabant without stating the salt or form; not verified as the hydrochloride form supplied as A11548. No dose conversion or lot validation.
METHODS > Drug treatments (S44, S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S152, S154); FIGURE 2 legend (S192)
western blot analysis in the dorsal hippocampus of mice at 10 months of age: western blot analysis in the dorsal hippocampus of mice at 10 months of age; comparator: Ts65Dn mice treated with vehicle — RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S152, S154); FIGURE 2 legend (S192)
Rimonabant 0.1 mg/kg/day; 0.5 mg/kg/day · METHODS > Drug treatments (S48, S49); RESULTS > Sustained oral administration of a low dose of rimonabant improves memory performance in young‐adult and middle‐aged Ts65Dn mice (S137, S154); FIGURE 2 legend (S192)